Journal
JOURNAL OF NEUROSCIENCE
Volume 33, Issue 11, Pages 5053-5064Publisher
SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.4361-12.2013
Keywords
-
Categories
Funding
- National Institutes of Health [RO1 AG030149]
Ask authors/readers for more resources
Neuroinflammation is an important component of Alzheimer's disease (AD) pathogenesis and has been implicated in neurodegeneration. Interleukin-1 (IL-1), a potent inflammatory cytokine in the CNS, is chronically upregulated in human AD and believed to serve as part of a vicious inflammatory cycle that drives AD pathology. To further understand the role of IL-1 beta in AD pathogenesis, we used an inducible model of sustained IL-1 beta overexpression (IL-1 beta(XAT)) developed in our laboratory. The triple transgenic mouse model of AD, which develops plaques and tangles later in its life cycle, was bred with IL-1 beta(XAT) mice, and effects of IL-1 beta overexpression on AD pathology were assessed in F1 progeny. After 1 and 3 months of transgene expression, we found robust increases in tau phosphorylation despite an similar to 70-80% reduction in amyloid load and fourfold to sixfold increase in plaque-associated microglia, as well as evidence of greater microglial activation at the site of inflammation. We also found evidence of increased p38 mitogen-activated protein kinase and glycogen synthase kinase-3 beta activity, which are believed to contribute to tau phosphorylation. Thus, neuroinflammation regulates amyloid and tau pathology in opposing ways, suggesting that it provides a link between amyloid accumulation and changes in tau and raising concerns about the use of immunomodulatory therapies in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available